The PAX5 gene is frequently rearranged in BCR-ABL1-positive acute lymphoblastic leukemia but is not associated with outcome. a report on behalf of the GIMEMA acute leukemia working party

Haematologica

Volumn 95, Issue 10, 2010, Pages 1683-1690

  Iacobucci, Ilaria ^a   Lonetti, Annalisa ^a   Paoloni, Francesca ^b   Papayannidis, Cristina ^a   Ferrari, Anna ^a   Storlazzi, Clelia Tiziana ^c   Vignetti, Marco ^b,d   Cilloni, Daniela ^e   Messa, Francesca ^e   Guadagnuolo, Viviana ^a   Paolini, Stefania ^a   Elia, Loredana ^d   Messina, Monica ^d   Vitale, Antonella ^d   Meloni, Giovanna ^d   Soverini, Simona ^a   Pane, Fabrizio ^f   Baccarani, Michele ^a   Foà, Robin ^d   Martinelli, Giovanni ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b GIMEMA Foundation   (Italy)

^c UNIVERSITY OF BARI   (Italy)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

^e UNIVERSITY OF TURIN   (Italy)

^f UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

All; BCR ABL1; PAX5

Indexed keywords

BCR ABL PROTEIN; DASATINIB; IMATINIB; STEROID; TRANSCRIPTION FACTOR PAX5;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER CHEMOTHERAPY; CHROMOSOME 9P; CHROMOSOME BREAKAGE; CHROMOSOME LOSS; CONTROLLED STUDY; COPY NUMBER VARIATION; DISEASE FREE SURVIVAL; DNA BINDING; EXON; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DELETION; GENE EXPRESSION; GENE INACTIVATION; GENE LOCUS; GENE REARRANGEMENT; GENETIC ASSOCIATION; GENOME ANALYSIS; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; HUMAN CELL; INCIDENCE; LEUKEMIA RELAPSE; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PHILADELPHIA 1 CHROMOSOME; POINT MUTATION; RE SEQUENCING; REAL TIME POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM;

ADOLESCENT; ADULT; AGED; B-CELL-SPECIFIC ACTIVATOR PROTEIN; FEMALE; FUSION PROTEINS, BCR-ABL; GENE DELETION; GENE REARRANGEMENT; GENOME-WIDE ASSOCIATION STUDY; HUMANS; MALE; MIDDLE AGED; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS;

EID: 77957796750     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2009.020792     Document Type: Article

References (38)

1. Cobaleda C, Schebesta A, Delogu A, Busslinger M. Pax5: the guardian of B cell identity and function. Nat Immunol. 2007;8(5):463-470.
2. Fuxa M, Skok JA. Transcriptional regulation in early B cell development. Curr Opin Immunol. 2007;19(2):129-136.
3. Nutt SL, Eberhard D, Horcher M, Rolink AG, Busslinger M. Pax5 determines the identity of B cells from the beginning to the end of B-lymphopoiesis. Int Rev Immunol 2001;20(1):65-82.
4. Fitzsimmons D, Hodsdon W, Wheat W, Maira SM, Wasylyk B, Hagman J. Pax-5 (BSAP) recruits Ets proto-oncogene family proteins to form functional ternary complexes on a B-cell-specific promoter. Genes Dev. 1996;10(17):2198-2211.
5. Horcher M, Souabni A, Busslinger M. Pax5/BSAP maintains the identity of B cells in late B lymphopoiesis. Immunity. 2001;14(6):779-790.
6. Ying H, Healy JI, Goodnow CC, Parnes JR. Regulation of mouse CD72 gene expression during B lymphocyte development. J Immunol. 1998;161(9):4760-4767.
7. Schebesta M, Pfeffer PL, Busslinger M. Control of pre-BCR signaling by Pax5-dependent activation of the BLNK gene. Immunity. 2002;17(4):473-485.
8. Morrison AM, Jager U, Chott A, Schebesta M, Haas OA, Busslinger M. Deregulated PAX-5 transcription from a translocated IgH promoter in marginal zone lymphoma. Blood. 1998;92(10):3865-3878.
9. Mullighan CG, Goorha S, Radtke I, Miller CB, Coustan-Smith E, Dalton JD, et al. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature. 2007;446(7137):758-764.
10. Mullighan CG, Williams RT, Downing JR, Sherr CJ. Failure of CDKN2A/B (INK4A/BARF)-mediated tumor suppression and resistance to targeted therapy in acute lymphoblastic leukemia induced by BCR-ABL. Genes Dev. 2008;22(11):1411-1415.
11. Kawamata N, Ogawa S, Zimmermann M, Niebuhr B, Stocking C, Sanada M, et al. Cloning of genes involved in chromosomal translocations by high-resolution single nucleotide polymorphism genomic microarray. Proc Natl Acad Sci USA. 2008; 105(33):11921-11926.
12. Bousquet M, Broccardo C, Quelen C, Meggetto F, Kuhlein E, Delsol G, et al. A novel PAX5-ELN fusion protein identified in B-cell acute lymphoblastic leukemia acts as a dominant negative on wild-type PAX5. Blood. 2007;109(8):3417-3423.
13. Cazzaniga G, Daniotti M, Tosi S, Giudici G, Aloisi A, Pogliani E, et al. The paired box domain gene PAX5 is fused to ETV6/TEL in an acute lymphoblastic leukemia case. Cancer Res. 2001;61(12): 4666-4670.
14. Nebral K, Konig M, Harder L, Siebert R, Haas OA, Strehl S. Identification of PML as novel PAX5 fusion partner in childhood acute lymphoblastic leukaemia. Br J Haematol. 2007;139(2):269-274.
15. An Q, Wright SL, Konn ZJ, Matheson E, Minto L, Moorman AV, et al. Variable breakpoints target PAX5 in patients with dicentric chromosomes: a model for the basis of unbalanced translocations in cancer. Proc Natl Acad Sci USA. 2008;105(44): 17050-17054.
16. Nebral K, Denk D, Attarbaschi A, König M, Mann G, Haas OA, Strehl S. Incidence and diversity of PAX5 fusion genes in childhood acute lymphoblastic leukemia. Leukemia. 2009;23(1):134-143.
17. Mullighan CG, Su X, Zhang J, Radtke I, Phillips LA, Miller CB, et al. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med. 2009;360(5): 470-480.
18. Mullighan CG, Miller CB, Radtke I, Phillips LA, Dalton J, Ma J, et al. BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature. 2008; 453(7191):110-114.
19. Vignetti M, Fazi P, Cimino G, Martinelli G, Di Raimondo F, Ferrara F, et al. Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome-positive patients with acute lymphoblastic leukemia without additional chemotherapy: results of the Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) LAL0201-B protocol. Blood. 2007;109(9): 3676-3678.
20. Le Coutre P, Ottmann OG, Giles F, Kim DW, Cortes J, Gattermann N, et al. Nilotinib (formerly AMN107), a highly selective BCRABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia. Blood. 2008;111(4):1834-1839.
21. Piccaluga PP, Paolini S, Martinelli G. Tyrosine kinase inhibitors for the treatment of Philadelphia chromosome-positive adult acute lymphoblastic leukemia. Cancer. 2007;110(6):1178-1186.
22. Ottmann O, Dombret H, Martinelli G, Simonsson B, Guilhot F, Larson RA, et al. Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study. Blood. 2007; 110(7):2309-2315.
23. Ottmann OG, Wassmann B. Imatinib in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukaemia: current status and evolving concepts. Best Pract Res Clin Haematol. 2002;15(4):757-769.
24. Martinelli G, Iacobucci I, Storlazzi CT, Vignetti M, Paoloni F, Cilloni D, et al. IKZF1 (Ikaros) deletions in BCR-ABL1-positive acute lymphoblastic leukemia are associated with short disease-free survival and high rate of cumulative incidence of relapse: a GIMEMA AL WP report. J Clin Oncol. 2009;27(31):5202-5207.
25. Foà R, Vitale A, Meloni G, Guarini A, De Propris S, Elia L et al. Dasatinib as front-line monotherapy for the induction treatment of adult and elderly Ph+ acute lymphoblastic leukemia (ALL) patients: interim analysis of the GIMEMA prospective study LAL1205. Blood. 2007; 110: 10a.
26. Foà R, Fazi P, Vitale A, Guarini A, De Propris MS, Elia L, et al. Dasatinib mono -therapy as 1st line treatment of Ph acute lymphoblastic leukemia (ALL) patients: update of Gimema LAL1205 study. Haematologica 2008: 93(s1):367 Abs.0922.
27. Iacobucci I, Storlazzi CT, Cilloni D, Lonetti A, Ottaviani E, Soverini S, et al. Identification and molecular characterization of recurrent genomic deletions on 7p12 in the IKZF1 gene in a large cohort of BCR-ABL1-positive acute lymphoblastic leukemia patients: on behalf of Gruppo Italiano Malattie Ematologiche dell'Adulto Acute Leukemia Working Party (GIMEMA AL WP). Blood. 2009;114(10):2159-2167.
28. Kaplan E, Meier P. Non parametric estimation from incomplete observation. J Am Stat Assoc. 1958;53:457-481.
29. Gooley TA, Leisenring W, Crowley J, Storer B. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat. Med. 1999;18(6):695-706.
30. Simon R, Lee Y. Nonparametric confidence limits survival probabilities and median survival time. Cancer Treat Res. 1982; 66(1):37-42.
31. Cox D. Regression models and life-tables. J R Stat Soc. 1972;34:187-220.
32. Familiades J, Bousquet M, Lafage-Pochitaloff M, Béné MC, Beldjord K, De Vos J, et al. PAX5 mutations occur frequently in adult B-cell progenitor acute lymphoblastic leukemia and PAX5 haploinsufficiency is associated with BCR-ABL1 and TCF3-PBX1 fusion genes: a GRAALL study. Leukemia. 2009;23(11):1989-1998.
33. Busslinger M, Klix N, Pfeffer P, Graninger PG, Kozmik Z. Deregulation of PAX-5 by translocation of the Emu enhancer of the IgH locus adjacent to two alternative PAX-5 promoters in a diffuse large-cell lymphoma. Proc Natl Acad Sci USA. 1996; 93(12):6129-6134.
34. Zwollo P, Arrieta H, Ede K, Molinder K, Desiderio S, Pollock R. The Pax-5 gene is alternatively spliced during B-cell development. J Biol Chem. 1997;272(15):10160-10168.
35. Arseneau JR, Laflamme M, Lewis SM, Maicas E, Ouellette RJ. Multiple isoforms of PAX5 are expressed in both lymphomas and normal B-cells. Br J Haematol. 2009;147(3):328-338.
36. Santoro A, Bica MG, Dagnino L, Agueli C, Salemi D, Cannella S, et al. Altered mRNA expression of PAX5 is a common event in acute lymphoblastic leukaemia. Br J Haematol 2009;146(6):686-689.
37. Georgopoulos K. Acute lymphoblastic leukemia-on the wings of IKAROS. N Engl J Med. 2009;360(5):524-526.
38. Souabni A, Cobaleda C, Schebesta M, Busslinger M. Pax5 promotes B lymphopoiesis and blocks T cell development by repressing Notch1. Immunity. 2002; 17(6):781-793.